Humanigen Inc (fka HGENQ)

[cowtown jay]

I think "running low on funds," at this point, is no longer a concern. Management is likely to recall the 110M shares they loaned, hopefully with an initial minimum asking price of $201. If we're still on the Expert Market when the loaned shares are recalled, short sellers will be crushed. It could cost them over $22B to cover their short positions.

As I recall, $22B used to be Novavax's market cap. It could be that again. But, if their European success is due to using lenz as a supplemental/replacement adjuvant, our market cap will skyrocket, also.

Hopefully, Humanigen would get a share of the money from the Advanced Purchase Agreement funds Novavax is receiving from several European countries. Maybe that will be the start of our revenue stream.

How much momentum we retain, as we transition to OTC Pink or Venture, before returning to Nasdaq, will be interesting to watch.